Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310106559> ?p ?o ?g. }
- W4310106559 endingPage "4670" @default.
- W4310106559 startingPage "4668" @default.
- W4310106559 abstract "Introduction Prognosis of patients with relapsed/refractory multiple myeloma (RRMM) is poor, particularly in triple-class refractory patients (refractory to a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody). Idecabtagene vicleucel (Ide-Cel) is the first chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell maturation antigen (BCMA) approved by both the European Medicines Agency and the US FDA and has been available in France through the Early Access Program for treatment (≥ 3 lines) of RRMM since June 2021. Approval was granted based on data from the KarMMa phase 2 trial including 54 patients receiving the approved dose that showed a response rate of 81%, complete response (CR) or better in 39% of patients, and an estimated median progression-free survival (PFS) of 12.1 months. However, up to now, real-world data are missing. In France, all patients treated with CAR T-cells including Ide-cel are consecutively enrolled in the DESCAR-T registry and clinical/biological data are directly collected from medical records which can be correlated with outcomes. Methods We conducted a multicenter, retrospective, observational study that included all consecutive patients with RRMM treated with Ide-Cel in France up to March 2022 who were registered in the DESCAR-T database of patients treated with CAR T therapy. The main objective was to analyze efficacy in terms of response rates: overall response rate (ORR), partial response (PR), very good PR (VGPR), CR, PFS and overall survival (OS). Secondary objectives included evaluation of safety in terms of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenia and infection. Results From June 2021 to December 2021, 53 patients were registered in DESCAR-T and underwent leukapheresis to be treated with Ide-cel, 49 (92%) were infused; 4 were not infused due to rapidly progressive disease and worsening clinical conditions. Median age of the 53 patients was 61 years (range 42-77), 66% were male, median number of prior treatment lines was 5 (range 2-8) including prior autologous stem cell transplantation (ASCT) in 49 (93%); 46 (87%) were triple-refractory, 38 (72%) were penta-refractory. At diagnosis, 6/33 (18%) had R-ISS stage III disease. Regarding high-risk cytogenetic abnormality, 9/34 had a del(17p), 6/36 had t(4;14), and 13/50 (26%) had extramedullary disease. Fourteen (26%) patients did not meet KarMMa inclusion criteria: cytopenia (n=4), kidney failure (n=3), performance score (PS) >1 (n=2), prior anti BCMA drug conjugate antibody (n=3), prior allograft (n=2). Forty-seven (89%) received bridging therapy of which 14 (30%) responded (13 PR; 1 VGPR). All patients received fludarabine-cyclophosphamide as the lymphodepletion regimen. Median time from apheresis to infusion was 64 days (range 51-131). Among the 49 infused patients, median follow-up after infusion was 4.2 months. At month (M)1, ORR was 88% (n=43) with 11 (23%) CR, 9 (19%) VGPR and 23 (47%) PR. At M3, ORR was 76% (n=34/45) with 3 (7%) SCR, 15 (33%) CR, 9 (20%) VGPR and 7 (16%) PR. Eighteen of 39 (46%) patients with non-progressive disease at M1 deepened their response at M3: 8 achieved CR (PR to CR n=5, VGPR to CR n=3). The 3-month PFS rate was 82% and OS at 3 months was 93%. CRS occurred in 45 (92%) patients, with 90% occurring within the first two days and only 1 case had severe (grade ≥ 3) CRS. ICANS occurred in 8 (16%) patients (3 with grade ≥ 3); 31 (63%) patients received tocilizumab, and 12 (24%) received steroids. Persistent cytopenia at M1 was observed in 35 (71%) patients with grade ≥ 3 thrombocytopenia, anemia and neutropenia in 17 (35%), 6 (12%) and 23 (47%) patients, respectively. Grade ≥ 3 infections were observed in 8 (16%) patients during the first month after infusion, including one patient with mucormycosis. At data cut-off, 8 patients died: 2 of acute toxicity (1 sepsis and 1 severe bleeding) and 6 of disease progression. Conclusion This study is the first European real-world multicenter retrospective study evaluating safety and efficacy of Ide-cel in patients with RRMM. Response rates and safety were comparable to those reported in the registration trial. Twenty-six percent of patients would not have been eligible for the KarMMa study and 72% were penta-refractory as compared to 15% in the 450x10^6” cohort in the KarMMa study. Longer follow-up and additional data will be presented at the ASH meeting." @default.
- W4310106559 created "2022-11-30" @default.
- W4310106559 creator A5004430833 @default.
- W4310106559 creator A5008084507 @default.
- W4310106559 creator A5011226625 @default.
- W4310106559 creator A5014723513 @default.
- W4310106559 creator A5016122215 @default.
- W4310106559 creator A5016941619 @default.
- W4310106559 creator A5020056942 @default.
- W4310106559 creator A5023945751 @default.
- W4310106559 creator A5024315315 @default.
- W4310106559 creator A5024552299 @default.
- W4310106559 creator A5027311948 @default.
- W4310106559 creator A5031216970 @default.
- W4310106559 creator A5032551623 @default.
- W4310106559 creator A5033496511 @default.
- W4310106559 creator A5036677725 @default.
- W4310106559 creator A5043831411 @default.
- W4310106559 creator A5047625349 @default.
- W4310106559 creator A5048560248 @default.
- W4310106559 creator A5050987906 @default.
- W4310106559 creator A5054214593 @default.
- W4310106559 creator A5058940187 @default.
- W4310106559 creator A5063422967 @default.
- W4310106559 creator A5075950291 @default.
- W4310106559 creator A5076452184 @default.
- W4310106559 creator A5082698003 @default.
- W4310106559 creator A5082733021 @default.
- W4310106559 creator A5083854975 @default.
- W4310106559 date "2022-11-15" @default.
- W4310106559 modified "2023-10-01" @default.
- W4310106559 title "French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry" @default.
- W4310106559 doi "https://doi.org/10.1182/blood-2022-162682" @default.
- W4310106559 hasPublicationYear "2022" @default.
- W4310106559 type Work @default.
- W4310106559 citedByCount "3" @default.
- W4310106559 countsByYear W43101065592023 @default.
- W4310106559 crossrefType "journal-article" @default.
- W4310106559 hasAuthorship W4310106559A5004430833 @default.
- W4310106559 hasAuthorship W4310106559A5008084507 @default.
- W4310106559 hasAuthorship W4310106559A5011226625 @default.
- W4310106559 hasAuthorship W4310106559A5014723513 @default.
- W4310106559 hasAuthorship W4310106559A5016122215 @default.
- W4310106559 hasAuthorship W4310106559A5016941619 @default.
- W4310106559 hasAuthorship W4310106559A5020056942 @default.
- W4310106559 hasAuthorship W4310106559A5023945751 @default.
- W4310106559 hasAuthorship W4310106559A5024315315 @default.
- W4310106559 hasAuthorship W4310106559A5024552299 @default.
- W4310106559 hasAuthorship W4310106559A5027311948 @default.
- W4310106559 hasAuthorship W4310106559A5031216970 @default.
- W4310106559 hasAuthorship W4310106559A5032551623 @default.
- W4310106559 hasAuthorship W4310106559A5033496511 @default.
- W4310106559 hasAuthorship W4310106559A5036677725 @default.
- W4310106559 hasAuthorship W4310106559A5043831411 @default.
- W4310106559 hasAuthorship W4310106559A5047625349 @default.
- W4310106559 hasAuthorship W4310106559A5048560248 @default.
- W4310106559 hasAuthorship W4310106559A5050987906 @default.
- W4310106559 hasAuthorship W4310106559A5054214593 @default.
- W4310106559 hasAuthorship W4310106559A5058940187 @default.
- W4310106559 hasAuthorship W4310106559A5063422967 @default.
- W4310106559 hasAuthorship W4310106559A5075950291 @default.
- W4310106559 hasAuthorship W4310106559A5076452184 @default.
- W4310106559 hasAuthorship W4310106559A5082698003 @default.
- W4310106559 hasAuthorship W4310106559A5082733021 @default.
- W4310106559 hasAuthorship W4310106559A5083854975 @default.
- W4310106559 hasBestOaLocation W43101065591 @default.
- W4310106559 hasConcept C121608353 @default.
- W4310106559 hasConcept C126322002 @default.
- W4310106559 hasConcept C141071460 @default.
- W4310106559 hasConcept C142424586 @default.
- W4310106559 hasConcept C143998085 @default.
- W4310106559 hasConcept C2776063141 @default.
- W4310106559 hasConcept C2776364478 @default.
- W4310106559 hasConcept C2776694085 @default.
- W4310106559 hasConcept C2777701055 @default.
- W4310106559 hasConcept C2778524551 @default.
- W4310106559 hasConcept C2780775027 @default.
- W4310106559 hasConcept C2780850621 @default.
- W4310106559 hasConcept C3875195 @default.
- W4310106559 hasConcept C71924100 @default.
- W4310106559 hasConcept C86803240 @default.
- W4310106559 hasConcept C87355193 @default.
- W4310106559 hasConceptScore W4310106559C121608353 @default.
- W4310106559 hasConceptScore W4310106559C126322002 @default.
- W4310106559 hasConceptScore W4310106559C141071460 @default.
- W4310106559 hasConceptScore W4310106559C142424586 @default.
- W4310106559 hasConceptScore W4310106559C143998085 @default.
- W4310106559 hasConceptScore W4310106559C2776063141 @default.
- W4310106559 hasConceptScore W4310106559C2776364478 @default.
- W4310106559 hasConceptScore W4310106559C2776694085 @default.
- W4310106559 hasConceptScore W4310106559C2777701055 @default.
- W4310106559 hasConceptScore W4310106559C2778524551 @default.
- W4310106559 hasConceptScore W4310106559C2780775027 @default.
- W4310106559 hasConceptScore W4310106559C2780850621 @default.
- W4310106559 hasConceptScore W4310106559C3875195 @default.
- W4310106559 hasConceptScore W4310106559C71924100 @default.
- W4310106559 hasConceptScore W4310106559C86803240 @default.
- W4310106559 hasConceptScore W4310106559C87355193 @default.